I am an activist investor in US and Chinese stocks. I was previously an investment banker in New York Hong Kong and London for 9 years, focused on Equity Capital Markets. I look at both long ideas and short ideas and typically focus on a small number on names where I can spend the time to conduct very deep research. I spend my time living between Los Angeles and Beijing, China.
Macro Investor | Mid/Long Term Horizon | US Equities, Commodities and Fixed Income | English, Dutch & German | Main Goal: Deliver the 1% of Global Data Needed To Make Money | Education | Ask Me Anything: firstname.lastname@example.org |
What to expect from my articles: I write mainly about my basic set of economic indicators that give a solid outlook about the economy. I then discuss trades that fit to the mid/long term outlook.
John Thomas graduated with a bachelor’s degree in biochemistry with honors and a minor in mathematics from the University of California at Los Angeles (UCLA) in 1974. He moved to Tokyo, Japan where he was employed by a medium-sized Japanese securities house. Thomas became fluent in Japanese and was trained as a domestic Japanese research analyst and money manager. In 1977 Thomas became the Tokyo correspondent for The Economist magazine and the Financial Times of London. Thomas traveled extensively throughout Asia, interviewing premiers, presidents and prime ministers, writing on macroeconomic trends, and producing countless features about individual companies. Thomas witnessed China’s cultural revolution and was one of the first American correspondents to enter China prior to the U.S. normalization of relations. Thomas authored several books about the Japanese financial system still in use by business schools today. In 1983 Thomas joined a top US investment bank in New York with the mandate to develop an international equity business for the firm. In 1985 he moved to London, England to establish a presence in Japanese equity derivatives for the firm. In 1989 Thomas was appointed a director of one of the big three Swiss Banks with a mandate to design sophisticated hedging strategies for the bank’s considerable holdings of Japanese equity warrants and convertible bonds. With the invasion of Kuwait by Iraq, Thomas was drafted by the US Marine Corp to serve as a pilot. In 1990 Thomas became a pioneer in the nascent hedge fund industry by founding the first dedicated Japanese hedge fund. The firm managed segregated accounts for a variety of government agencies, banks, and high net worth individuals in Europe, the Middle East, and Asia. After a decade of spectacular absolute and relative performance he sold his firm in 1999 and retired to manage his personal investments in the oil and gas industry. Seeing incredible opportunities in the marketplace and yearning for the adrenaline and satisfaction offered by active management, Thomas launched a new hedge fund in 2007. In his free time Thomas is a commercial aircraft pilot, long distance hiker and mountain climber, wine collector and avid photographer.
Theodore J. Cohen, Ph.D., a research scientist, has been an investor for more than 50 years. Since 1980, he has focused his attention on investment research and investigative analyses of companies developing therapeutic drugs in the biotech sector. Dr. Cohen is a frequent contributor of Guest Opinions (op-ed pieces) to the Bucks County (PA) Courier Times (circulation: 80,000), where, since 2007, he has addressed such varied subjects as the conflicts of interest (COIs) associated with two members of the Provenge advisory committee (AC); the U.S. Senate’s Durbin Amendment, to tighten COI reviews of FDA AC members; and naked short selling. Cohen is the author of the award-winning novels Death by Wall Street: Rampage of the Bulls (AuthorHouse, 2010) and House of Cards: Dead Men Tell No Tales (Outskirts Press, 2011), which were inspired by real events. The books are available from Amazon.com, B&N, and 26,000 online bookstores worldwide. For details, see http://www.theodore-cohen-novels.com.
I am a Master of the arts but am involved in many types of investing and trading. My areas of research are primarily biotechnology and disruptive technology. I am interested in turnaround, contrarian, trend following, and (deep) value situations.
I am developing proprietary, quantitative investment strategies; and I operate a website for investors and others.
Formerly Chief Market Strategist at Capital Ladders Advisory Group LLC. After the sale of certain of CLAG's retail and institutional assets in October 2015, I have commenced my latest venture in the CPG industry which is centered on the development and licensing of consumer and commercial technology. https://www.linkedin.com/profile/view?id=AAIAAA3lJ9IBNi1rhhFzRWElkJl4MpyNuIiHglQ&trk=nav_responsive_tab_profile
CooLinX Integrated Technologies develops technologies for the beverage and CPG industry. We are presently effecting licensing agreements with multi-national brands and co-developing products aimed for mass market consumption.
Gary A. Gordon, MS, CFP® is the president of Pacific Park Financial, Inc., a Registered Investment Adviser with the SEC. He has more than 25 years of experience as a personal coach in “money matters,” including risk assessment, small business development and portfolio management.
Gary is often asked to consult as an educator. He has taught financial concepts in Mexico, Singapore, Hong Kong, Taiwan and the United States.
As a Certified Financial Planner™ (CFP®), Gary has distinguished himself as a reputable and trusted investor advocate. He writes commentary for ETF Expert, Seeking Alpha and The Street. Gary’s participation on local and national radio has spanned more than a decade, and he currently hosts the ETF Expert Show.
Gary is a “good sport” when his wife, Denise, beats him at Scrabble. Most of all, Gary takes special pride in a not-so-little energizer… his 20-year old daughter, Wei Gordon.
I worked in New York's financial sector for almost exactly 20 years, mostly as a healthcare analyst (drugs, biotech, and medical devices), but also as an assistant research director, portfolio manager, and options strategist. My last formal job had me in charge of Value Line's premium priced "Select" and "Special Situation" products. The former highlights the company's top stock pick of each month and the latter introduces relatively small companies. I quit that job in June, 2009 for reasons that a dozen or so confidentiality agreements preclude my discussing. In September of that year, I launched 3DimensionalResearch.com (3DR), which allows me to continue doing what I was doing previously.
I am a strong believer in maximum transparency, in both personal and business relationships. So, in that vein:
A google search will show that my former employer sued 3DR and me in November, 2009 for copyright infringement, hot news misappropriations, and the proverbial kitchen sink. Although a search won't show this, unfortunately, I represented myself in a federal courtroom in December and, in accordance with the judge's instructions, the case was settled in a matter of minutes.
Additional Disclosure: 3DR has been a financial failure thus far, in terms of getting subscribers. I detest marketing and few people want to pay for information anymore, least of all from a no-name website. That said, the vast majority of my recommendations have done very well and my personal portfolio is doing extraordinarily well (65.5% in 2013) since I tend to follow most of my own recommendations, the "event driven special situations," in particular.
MD, MBA (Finance, NYU-Stern), certificate in financial modeling (Wharton). *Tipranks profile not accurate as doesn't pick up my premium ratings. Founder: Vasuda Healthcare Analytics (premium U.S. Biotech/pharma research) and Trident Asian Research (premium Asian investments research, www.tridentasia.com)
- Investment insights contributor: SumZero, Buy-side Institutional Platform (sumzero.com). Members of the platform include some of the largest hedge funds and asset managers.
-Former Insight Provider for Smartkarma Intelligent Investing (www.smartkarma.com): Institutional Investments Research Platform (was ranked among top 10 out of over 100 contributors). Clients included some of the largest hedge funds and asset managers.
- Buy-side equity research analyst covering mainly small-cap, emerging pharma/ biotech companies. M.D. with over 18 years of clinical experience (in the U.S. and India), still retaining full medical license in India. M.B.A. with finance and financial markets specialization from New York University Stern School of Business.
- Expert in picking healthcare-related investments, especially biotechnology and pharmaceuticals (focus on small, emerging companies). Investments are selected based on detailed due diligence, including proprietary DCF valuation models. Value investor with long-term horizon.
- Founder, managing principal of Vasuda Capital Management, healthcare-focused investment management firm, vasudacapitalmanagement.com. Registered Investment Advisor in Massachusetts.
- Also started and continue to sponsor Vasuda Global Orphan/ Rare disease biotechnology index, the first global equity index covering rare/orphan disease sector. Index quotes are available on bloomberg/reuters terminals.
Slingshot Insights is the first crowdfunded expert network and due diligence community. Members use our suite of tools to cut through the noise and Become the Smart Money. We provide you affordable access to Experts and Management Teams so that you can make informed investment decisions. By grouping investors around project ideas they care about, we pass along significant savings without compromising on quality.
I am an individual and occasional investor with a passion for biotechnology and stocks. I am working as an engineer with ties to the healthcare sector.
I build investment theses based on thorough personal research and end up picking only stocks that I think hold a very high and long-term potential. I specialize in micro-cap and/or European biotechs, tracking undervalued opportunities and basing my investment choices on the deep analysis of a company's fundamentals and its long-term perspective (at least several years).
Follow me on twitter: https://twitter.com/Logribel
Saibus Research is an independent research firm that specializes in fundamental deep value research in public securities for fund managers and institutional investors. We don't sell reports, we sell expertise.
For real-time updates: @saibusresearch
Medical doctor and independant investor. My investment strategy is to utilize my medical education, combined with market technical and fundamental analysis, to find undervalued biopharmaceutical investments which have a high likelihood of increasing in value over a specified time period. I look for companies whose stocks have recently dropped due to technical factors, misunderstood data or undervalued market opportunity among other factors.
If you are interested in any of my digital utility solutions to add to your investing tool box to improve your investment outcomes, please visit my site
You'll find elegant applications that make it simple for you to track your portfolio in real time, make a watch list to follow in real time, track your dividend income and growth, and other applications. These applications will allow you to set alerts at prices you choose in order to obtain the yield and income that you want. They function as real time trade assistants and will improve your investment performance. You can even mirror the successful FTG Portfolio with "My FTG Mirror Calculator", and subscribers can mirror the premium subscriber portfolio with "MY RODAT Mirror Calculator" if they wish to emulate the out performance we've achieved in capital and income growth.
I am a retired clinical psychologist, and administrator and owner of a rehabilitation clinic we founded 40 years ago. For over 55 years I have managed several portfolios composed of investments accumulated over our professional careers. Since the financial crisis of 2008, I have employed specialized, customized dividend growth strategies aimed at enhancing and growing a dividend income stream.
Since December 24, 2014, I have demonstrated on Seeking Alpha the ongoing construction and portfolio management of the Fill-The-Gap Portfolio aimed at highlighting strategies investors may utilize to close the gap between an average Social Security benefit and the much greater costs faced in retirement.
This portfolio has outperformed all of the broad market indexes by a very wide margin, growing dividend income and total portfolio value consistently while the broader indexes struggle in negative territory all year.
Aside from free articles available to the general public, additional early-access, value-added ideas and deep-dive articles are offered to paid subscribers on my premium SA platform, "Retirement: One Dividend At A Time"
Let me show you how to build and grow your portfolio and dividend income, step by step, towards a comfortable and secure retirement.
A new age platform for the latest in finance and everything else.
Through Bidness Etc, we’re bringing the 99% back in the loop by presenting the best financial research in the simplest and most creative ways possible.
We have distilled a decade and billions of dollars’ worth of trading experience into developing the idea behind Bidness Etc, and we feel we can do a better job of analyzing and reporting financial matters than anyone else.
We are a team of more than 60 financial wizards, musicians, rock stars, artists, singers, aspiring philosophers and tech geeks working hard to change the way human beings think and interact with finance.
We know that quality financial analysis requires a higher level of intelligence, and that what is reported by financial media is too far behind the curve to be of any relevance to the savvy reader. Here’s our solution to that problem: a platform that gives away the best information and analysis out there for free, thereby democratizing individuals’ access to finance. We’re also pushing the envelope by delivering it visually.
We feel that by doing so, Bidness Etc. will become humanity’s first step into a new age for financial media, and that we’ll set the standards for tomorrow with our revolutionary new product.
And that’s not all.
We know that figures, facts, numbers and stats can get quite mind-numbing after a while. Therein lies the kicker: we’re presenting our data in the most visually appealing ways possible. By doing so, we are quite literally transforming financial reporting into a new form of art. We have also incorporated an entertainment section in our website, which tracks the global zeitgeist and provides our take on the hottest topics trending on the web. We feel that this will help us take finance to the mainstream, and complete what the Bidness Etc. experience is all about.
This is a beta version of our web portal. We hope it will keep you coming back for more, because we have a major surprise in store for readers for the month of November. Here’s a spoiler, though: finance will never have looked better once we go all out! And you’ll know we’ve meant Bidness all along when we claim to become the best place on the web.
F.A.S.T. Graphs™ is a powerful research tool providing “essential fundamentals at a glance” on over 17,000 symbols. F.A.S.T. Graphs™ empowers the user to research stocks deeper and faster by allowing them to exploit the undeniable relationship and functional correlation between long-term earnings growth and market price. Warren Buffett, the greatest capital allocator of all time, said; “there are only two things that investor needs to know; how to value a company and how to think about stock prices.” With the F.A.S.T. Graphs™ at their disposal, users are able to perform both of these critical tasks… FAST. F.A.S.T. is an acronym for Fundamentals Analyzer Software Tool that takes all the hours of manual graphing of business fundamentals and reduces it to seconds, giving you critical information in an instant. With one glance you know a lot about the business you are graphing and its past, present and future value. F.A.S.T. Graphs™ should be the first step in every research project. Each graph is worth 1,000 words in describing a company’s growth, consistency and valuation.
After spending a dozen years making a big name for herself as a highly respected investigative reporter in the financial arena, Melissa Davis took a chance on her longtime dream in 2015 by becoming her own boss so that she could pour even more time and energy into uncovering the truth about suspicious public companies by conducting the deepest research of her award-winning career. At that point, Ms. Davis had already established herself as a fearless journalist with an impressive talent for exposing corporate fraud. Most recently, she served as the founding editor of TheStreetSweeper, a financial news website dedicated to warning investors about risky stocks that she essentially built from scratch. Under her leadership, TheStreetSweeper soon earned steady applause from some of the biggest names in the business and continued to flourish for years. Prior to launching that well-known website, Ms. Davis spent seven years on the staff of TheStreet.com -- an even more prominent financial outlet founded by "Mad Money" host Jim Cramer -- where she quickly rose to become one of the leading investigative reporters on a large and impressive editorial team. Already the recipient of numerous awards by the time that TheStreet.com hired her away from the largest newspaper in her home state, Ms. Davis went on to land a national prize for enterprise reporting from the Society of American Business Editors and Writers (SABEW) by the time that her tenure there came to an end. Today, she spends her days (and, when necessary, plenty of late nights) trying to do what she has always done the best even better: revealing the dirty secrets about publicly traded companies that investors desperately need -- and inherently deserve -- to know! (She also smothers her adorable granddaughter -- the other great love of her life -- with plenty of hugs and kisses at every available chance.)
Our stock holdings are set forth below.
Own over 50 dividend paying stocks. Our holdings by sector. Animal Health/Dental: PDCO. Chemical/Agriculture: DOW, DD, FMC and MON. Consumer Defensive: KO, PG, MO, KMB, GIS, MDLZ, CLX, CL, KHC, HSY and SJM. Consumer Cyclical: SBUX, NKE and COH. Healthcare: ABT, ABBV, BMY,BAX, DGX, JNJ, MJN, LLY, PFE, MRK and HYH. Tech: ADP, ORCL, IBM, INTC, GLW, HPQ, HPE, NATI and TXN. Industrial: EMR, ITW, JCI, MMM, HON and GE. Telecom: T and VZ. Utility: AEP Miscellaneous: AVY, CDK, FAST, FBHS, SPGI and VSM.
Ian’s Insider Corner research focuses primarily on long-term dividend-paying companies with stable and reliable growth, stocks suitable for individual retirement accounts. Ian also looks for “niche” shorter-term trading opportunities, and coverage. During the 3-years Ian worked at Kerrisdale Capital, the New York-based activist hedge fund had great success exposing fraudulent companies. Kerrisdale Capital returned almost 200% in 2011, and more than 300% in total. Ian Bezek offers in-depth coverage of all the stocks in his “IMF” portfolio.
I have recently left my job as a Financial Credit Analyst at one of the Big-4 US banks to venture off on my own to start an Investment Management firm called Stockmeister Capital. Stockmeister Capital will manage investments funds for both Qualified and Non-Qualified investors.
My investment style is heavily influenced by Warren Buffett and nearly all of my investment ideas revolve around a monopolistic business. I look for companies with strong business models, significantly undervalued earnings power, predictable earnings, and a long runway for future growth.
I also like watching/playing sports, hunting for antique books or historical items, and playing card or board games.
Chris Damas' contrarian equity research is broad based and covers energy production and infrastructure, metals, agriculture, chemicals, forestry, industrials, telecoms, retail, technology, financials, transports, renewables and special situations as well as US MLP's. Chris managed the second largest preferred share portfolio on Bay Street during the 80's and also follows currency and fixed income markets closely. His investment universe is broad and he spends most of his time hunting for actionable trade ideas and long term investment opportunities. His investment thinking and trading activity are now only available by subscribing to the US and Canadian versions of The BCMI Report (trademark) and The BCMI Flash (trademark) which are issued at least weekly and more frequently when opportunities and market conditions demand it.
I am a CPA, CFE and have a BA in finance. I don't like to lose money.
If there are any bank stocks you would like to have regular quarterly/semi-annual coverage on let me know, I add a lot of names throughout the year but want to provide regular coverage for interested readers.
The author is the honourable CFA Scholarship recipient. His interests are in the technology, healthcare, consumer space and gaming. He is now an analyst with an asset management firm
His work in the buy side gives him access to the Bloomberg terminal, access to management and sell-side analysts. One can see that in every single piece of his article.
This is something you will not see anywhere else. When you follow me, you directly benefit from this service.
Here are some of my calls below: [Don't just take my word for it, check it out yourselves]
Articles (As of 1st October 2015)
1) Las Vegas Sands down 29% in 3 months since Sell initiation [http://seekingalpha.com/article/3390785-upgrading-bdx-before-results-announcement]
2) Alibaba down more than 30% in 3 months since Sell Initiation- http://seekingalpha.com/article/3432076-alibaba-down-more-than-10-percent-in-a-month-since-sell-report-reiterate-sell
3) China Distance Education up 16% in 2 weeks since Buy Initiation- http://seekingalpha.com/article/3538526-china-distance-education-holdings-up-15_9-percent-in-2-weeks-now-what
4) OnDeck Capital down 30% in less than a month since Sell Initiation - http://seekingalpha.com/article/3330155-ondeck-capital-initiation-report
Liu is currently the CEO of Capitol Isle Partners LLC a media consulting business focusing on corporate restructuring and new business development. He is a partner in Information Central, a newsletter content provider and web marketing company. He also serves as a Senior Advisor to Goldmark Advisors, an investment banking boutique specializing in media situations. Liu has been a successful start-up and turnaround specialist in the media and publishing industry. He has spent his career advising companies in the fields of publishing, direct marketing and web-partnership marketing. In the past several years, he has consulted via Capital Isle Partners with well-known clients such as TV Guide, Primedia, Evercore Partners, Boardroom Reports and Willis Stein Partners. Before becoming a consultant, Liu has held several prestigious assignments. He was the Vice President of Consumer Marketing for American Media, Inc., publishers of The National Enquirer, STAR Magazine. Liu served as the Executive Vice President and co-founder of Lear Publishing, a consumer magazine company founded by Frances Lear (Norman Lear's ex-wife). He was also the President and Publisher of Network Publishing, the magazine division of the Providence Journal Company, and executed the hugely successful turn around of Soap Opera Digest. Liu is a long time investor focusing on value and strategic plays where his business experience in turnaround and restructuring work can be used to find and define opportunities in the market.